ACM
BHVN

Aisling Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Aisling Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-274,513
Closed -$12M – 14
2019
Q2 		$12M Hold
274,513
– – 5.13% 6
2019
Q1 		$14.1M Hold
274,513
– – 10.76% 4
2018
Q4 		$10.2M Buy
+274,513
New +$9.9M 10.69% 5

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Aisling Capital Management's BHVN Position: Q3 2019 in Review

Aisling Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2019, closing a stake of 274,513 shares — an estimated $12M sold.

Aisling Capital Management first reported a position in BHVN in Q4 2018 and held it in 3 quarters. The position peaked at $14.1M in Q1 2019. 184 funds tracked by Wall St. Rank hold BHVN as of Q3 2019.

  • Aisling Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2019 after selling out during the quarter.
  • Aisling Capital Management sold 274,513 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2019, an estimated $12M.
  • Aisling Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2018 and held it in 3 quarters.
  • Aisling Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $14.1M in Q1 2019.
  • 184 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2019.

Based on Aisling Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.